A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
University of Pittsburgh
PharmaMar
Instituto do Cancer do Estado de São Paulo
Vastra Gotaland Region
Xencor, Inc.
Infinity Pharmaceuticals, Inc.